ScholarIQanswers from OpenAlex & ORCID
Antonio Llombart‐Cussac
ResearcherPublications, citations & collaboration network
Antonio Llombart‐Cussac is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Antonio Llombart‐Cussac have?
ScholarIQindexed works
Antonio Llombart‐Cussac has 702 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Antonio Llombart‐Cussac have?
ScholarIQcitation count
Antonio Llombart‐Cussac has 16,756 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Antonio Llombart‐Cussac?
ScholarIQh-index
Antonio Llombart‐Cussac has an h-index of 60 in OpenAlex.
What is the i10-index of Antonio Llombart‐Cussac?
ScholarIQi10-index
Antonio Llombart‐Cussac has an i10-index of 205 in OpenAlex.
What is the ORCID of Antonio Llombart‐Cussac?
ScholarIQorcid
The ORCID for Antonio Llombart‐Cussac is on the source record.
What is the OpenAlex record for Antonio Llombart‐Cussac?
ScholarIQopenalex
The OpenAlex for Antonio Llombart‐Cussac is on the source record.
What are the most-cited papers on Antonio Llombart‐Cussac?
ScholarIQmost cited works
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study
W. Eiermann, Stefan Paepke, Justus Appfelstaedt, Antonio Llombart‐Cussac, J. Eremin, J. Vinholes, L. Mauriac, Matthew J. Ellis, M. Lassus, Hilary A. Chaudri‐Ross, Margaret Dugan, M. Borgs, Semiglazov Vf
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
François‐Clément Bidard, Stefan Michiels, Sabine Riethdorf, Volkmar Müller, Laura J. Esserman, Anthony Lucci, Bjørn Naume, Jun Horiguchi, Rafael Gisbert‐Criado, Stefan Sleijfer, Masakazu Toi, José Á. García-Sáenz, Andreas D. Hartkopf, Daniele Generali, Françoise Rothé, Jeffrey B. Smerage, Laura Muinelo‐Romay, Justin Stebbing, Patrice Viens, Mark Jesus M. Magbanua, Carolyn Hall, Olav Engebraaten, Daisuke Takata, José Vidal-Martínez, Wendy Onstenk, Noriyoshi Fujisawa, Eduardo Díaz‐Rubio, Florin‐Andrei Taran, Maria Rosa Cappelletti, Michail Ignatiadis, Charlotte Proudhon, Denise M. Wolf, Jessica B. Bauldry, Elin Borgen, Rin Nagaoka, Vicente Carañana, Jaco Kraan, Marisa Maestro, Sara Y. Brucker, Karsten E. Weber, Fabien Reyal, Dominic Amara, Mandar Karhade, Randi R. Mathiesen, H. Tokiniwa, Antonio Llombart‐Cussac, Alessandra Meddis, Paul Blanche, Koenraad D’Hollander, Paul Cottu, John W. Park, Sibylle Loibl, Aurélien Latouche, Jean‐Yves Pierga, Klaus Pantel
Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer
Luca Gianni, José Baselga, W. Eiermann, Vincente Guillem Porta, Semiglazov Vf, Aňa Lluch, Milvia Zambetti, Dolores Sabadell, Günther Raab, Antonio Llombart‐Cussac, А. А. Божок, Ángel Martínez-Agulló, Marco Greco, Mikhail Byakhov, Juan José López Gómez, Mauro Mansutti, Pinuccia Valagussa, Gianni Bonadonna
Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy
Luca Gianni, José Baselga, W. Eiermann, V. Guillem Porta, Semiglazov Vf, Aňa Lluch, Milvia Zambetti, Dolores Sabadell, Günther Raab, Antonio Llombart‐Cussac, А. А. Божок, Ángel Martínez-Agulló, Marco Greco, Mikhail Byakhov, Juan José López Gómez, Mauro Mansutti, Pinuccia Valagussa, Gianni Bonadonna, European Cooperative Trial in Operable Breast Cancer Study Group